Catalog No.
DHD68903
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Concentration
2.57 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P25942
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CP-870, 893, RG-7876, RO-7009789, CAS: 1622140-49-1
Clone ID
Selicrelumab
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients, PMID: 33097612
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, PMID: 21436454
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer, PMID: 34112709
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia, PMID: 34205588
Immunotherapy of cancer in 2012, PMID: 22576456
Agonistic CD40 Antibodies in Cancer Treatment, PMID: 33804039
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5), PMID: 31275618
Dual Immunotherapies Shrink Melanomas, PMID: 25998399
Harnessing immune responses in the tumor microenvironment: all signals needed, PMID: 24097857
Poking CD40 for cancer therapy, another example of the Goldilocks effect, PMID: 21057206
CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome, PMID: 22459705
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters, PMID: 28619093
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, PMID: 26386124
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, PMID: 17327609
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice, PMID: 21479995
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, PMID: 23983255
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893, PMID: 20842056
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation, PMID: 19906293
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors, PMID: 20855968
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model, PMID: 17444959
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma, PMID: 25252722
For research use only. Not for human or drug use.
